Welcome to the Bioasis Technologies Hub On AGORACOM

Message: Roche Brain Shuttle Enters Clinical Trials

Yesterday, I saw an Evaluate Vantage article by Jacob Plieth indicating that Roche's anti-transferrin receptor brain shuttle has entered Phase 1 clinical trial for anti-amyloid beta antibody. 

Roche tries another way to solve the amyloid-beta conundrum

Here is a link to their clinical trial:

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

As far as I know, this is Roche's first brain shuttle molecule to enter clinical trials. Anyone else know of another? If true, then it is very surprising that Roche would start in Alzheimer's and with an amyloid beta approach. So many failures in testing the amyloid beta hypothesis. Could these past failures be overcome by increased brain penetration of the antibody? 

Also noteworthy that MedImmune's two studies below concluded that the xB3/LRP1 approach outperformed the transferrin receptor antibody approach.

New Message
Please login to post a reply